Introduction {#s1}
============

Signaling through RET plays essential regulatory roles in the development of the nervous system and kidney ([@bib23]). Dysregulation of RET signaling is linked to many human diseases, such as Hirschsprung\'s disease, a disorder characterized by lack of enteric ganglia in parts of the intestine, and multiple endocrine neoplasia type 2 (MEN 2A and 2B) ([@bib23]). Glia cell line-derived growth factor (GDNF), Neurturin (NRTN), Artemin (ARTN) and Persephin are four ligands that induce dimerization of RET through assembling 2:2:2 ternary complexes with RET and the co-receptors GDNF receptor-α family proteins (GFRα1--4) ([@bib23]; [@bib6]; [@bib13]; [@bib31]; [@bib37]; [@bib57]). The kinase domain of dimerized RET mediates trans-phosphorylation of a number of tyrosine residues in the cytoplasmic region, leading to activation of downstream signaling pathways, including the Ras/MAP kinase cascade and the PI3 kinase/AKT pathway ([@bib23]). Recently, growth and differentiation factor 15 (GDF15) and GFRα-like protein (GFRAL) have been identified as a new ligand/co-receptor pair for RET ([@bib16]; [@bib22]; [@bib39]; [@bib61]). GFRAL expression is largely restricted to the area postrema and nucleus tractus solitarius in the hindbrain. Activation of RET by GDF15 and GFRAL in these regions leads to suppression of food intake and reduction of body weight in response to environmental stresses ([@bib16]; [@bib22]; [@bib39]; [@bib61]; [@bib25]). More recently, GDF15-promoted metabolic adaption has been shown to have tissue protective effects during systemic inflammation caused by bacterial and viral infections ([@bib33]). Therefore, this newly discovered GDF15/GFRAL/RET signaling pathway may be targeted for treating obesity and preventing infection-induced tissue damage. In addition, GDF15 is known to be highly expressed in placenta trophoblasts and many cancers, likely contribute to anorexia in pregnant women and cancer patients, respectively ([@bib19]). The identification of the GDF15/GFRAL/RET pathway provides the mechanism and new therapeutic targets for these conditions.

Both RET and the co-receptors are expressed on the cell surface and use their extracellular domains to interact with the ligands. Several structures of the complexes between ligands and co-receptors of RET have been solved by X-ray crystallography, which all display a 2:2 architecture where each subunit in the dimeric ligands binds the second domain (D2) of one co-receptor molecule ([@bib22]; [@bib47]; [@bib60]; [@bib43]). The angle between the two halves of these 2:2 complexes however differ substantially ([@bib22]; [@bib43]), raising the question how such different configurations of the ligands/co-receptors are all capable of inducing the activation of the RET kinase. The extracellular region of RET contains four atypical cadherin-like domains (CLD1-4) followed by a cysteine-rich domain (CRD) ([Figure 1A](#fig1){ref-type="fig"}), which have all been implicated in interacting with ligands or co-receptors ([@bib21]; [@bib3]). The crystal structure of the CLD1-2 tandem shows an unusual clamshell-like arrangement ([@bib29]), whereas high-resolution structures of the other domains in the RET extracellular region are not available. The structure of the intact RET extracellular region in complex with GDNF and GFRα1 has been determined at low resolution by negative-stain electron microscopy (EM), showing an overall batwing-like shape in which the two wing-shaped RET molecules are tethered together by the dimeric GDNF/GFRα1 complex in the middle, and suggesting that the CRD is important for the dimerization and activation of RET ([@bib21]). This structure however does not clearly resolve the individual domains in RET or their interactions with GDNF and GFRα1. In particular, the conformation and location of the membrane proximal domain CRD in RET remain unclear. High-resolution structures of RET ternary complexes are required for addressing the questions how the different ligands and co-receptors interact with RET and whether they can lead to different downstream signaling.

![Overall structures of four different RET ternary complexes.\
(**A**) Domain organization of the ligands, co-receptors and RET. The domains in gray are absent in the cryo-EM structures. (**B**) Cartoon representations of the four RET ternary complexes. The angles between the two wings are indicated -in the side views. Dotted lines indicate the connection from the CRD to the transmembrane region of RET.](elife-47650-fig1){#fig1}

Here, we report the cryo-EM structures of four extracellular 2:2:2 ligand/co-receptor/RET complexes, including GDF15/GFRAL/RET, GDNF/GFRα1/RET, NRTN/GFRα2/RET and ARTN/GFRα3/RET, at near-atomic resolution. The structures show that the extracellular region of RET adopts a 'C-clamp' shape, which is stabilized by extensive inter-domain interactions as well as binding of calcium ion at multiple sites. Due to this unique C-clamp shape, the recruitment of two RET molecules onto dimeric ligand/co-receptor complexes brings the two RET-CRDs to close proximity to promote the dimerization and trans-autophosphorylation of the intracellular kinase domain. Surprisingly, our cryo-EM results reveal that two 2:2:2 NRTN/GFRα2/RET complexes can dimerize to form a 4:4:4 complex through a novel ligand/receptor interface. We found that the 4:4:4 complex suppresses RET endocytosis. These findings suggest that, while activating RET through a common mechanism, the different ligands can use distinct interactions and mechanisms to fine-tune RET activity, which may lead to different signaling outcomes.

Results {#s2}
=======

Structure determination of RET extracellular ternary complexes {#s2-1}
--------------------------------------------------------------

To understand the activation mechanisms of RET by different ligands, we successfully reconstituted four RET extracellular ternary complexes, GDF15/GFRAL/RET, GDNF/GFRα1/RET, NRTN/GFRα2/RET and ARTN/GFRα3/RET, for cryo-EM structure determination ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The initial 3D reconstruction of the 2:2:2 GDF15/GFRAL/RET complex with 2-fold symmetry applied was determined at relatively low-resolution (4.0 Å), partly due to the relative movement between the two wings in the batwing-shaped complexes. To improve the resolution, we used the symmetry expansion approach as well as focused refinement with signal subtraction as described in our previous work ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"}--[4](#fig1s4){ref-type="fig"}) ([@bib5]; [@bib66]). The resulting reconstruction comprising one RET and GFRAL with the GDF15 dimer bound reached 3.7 Å resolution. This reconstruction in combination with the intact map with the 2-fold symmetry allowed us to build an accurate atomic model for the entire 2:2:2 complex ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). The same procedure was used for the structure determination of the 2:2:2 NRTN/GFRα2/RET and ARTN/GFRα3/RET complexes, leading to reconstructions to 3.4 Å and 3.5 Å resolution, respectively ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The reconstruction of the GDNF/GFRα1/RET complex reached lower resolution (4.4 Å) due to preferred orientation of particles (see Materials and methods for details) ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

Overall architecture of RET extracellular ternary complexes {#s2-2}
-----------------------------------------------------------

All four complexes show the same batwing-like architecture as shown in the previously reported negative-stain EM structure of the GDNF/GRFα1/RET ([@bib21]), with the dimeric ligands located at the center connecting the two wings formed together by RET and the co-receptors ([Figure 1](#fig1){ref-type="fig"}). A recently published medium resolution (5.7 Å) cryo-EM structure of the NRNT/GFRα2/RET complex displays a similar overall architecture ([@bib7]). The outer edge of the wing is defined by RET, which assumes an overall 'C'-shape to clamp on both the ligands and co-receptors. Low-resolution reconstructions of RET in the apo-state with cryo-EM by us ([Figure 1---figure supplement 5C](#fig1s5){ref-type="fig"}) and with small-angle X-scattering reported previously both show a similar C-clamp shape ([@bib21]), suggesting that the RET extracellular region is relatively rigid and does not undergo substantial conformational changes upon binding of the ligands/co-receptors. Extensive interactions are formed between the consecutive domains in the RET extracellular region, explaining this rigidity ([Figure 2A--2D](#fig2){ref-type="fig"}). As expected, all the four CLDs in RET adopt the cadherin-like fold characterized by a two-layered β-sandwich. CLD1 and CLD2 pack tightly against each other to form the clamshell-like structure as shown in the published crystal structure of these two domains ([Figure 2A](#fig2){ref-type="fig"}) ([@bib29]). CLD3 is connected to CLD2 with an inter-domain angle of \~ 144°, which is maintained by binding of three calcium ions at the inter-domain junction ([Figure 2B](#fig2){ref-type="fig"}). The calcium ions are coordinated by a number of conserved negatively charged residues from CDL2 and CLD3 that have been identified as classical cadherin calcium-binding motifs and important for the correct folding of RET ([Figure 2B](#fig2){ref-type="fig"}) ([@bib21]; [@bib58]; [@bib30]; [@bib4]). The inter-domain angle between CLD3 and CLD4 is \~ 130°, leading to a smooth curved shape of CLD2, CLD3 and CLD4. The interface between CLD3 and CLD4 is dominated by hydrophobic residues ([Figure 2C](#fig2){ref-type="fig"}). CRD docks onto CLD4 in an orthogonal orientation through an extensive interface containing both hydrophobic and polar interactions, completing the bottom portion of the C-clamp ([Figure 2D](#fig2){ref-type="fig"}).

![Structure of the RET extracellular domain.\
(**A--D**) Overall structure and the inter-domain interactions in the RET extracellular region. (**E**) Structure of the CRD domain of RET. The expanded view shows the details of the putative calcium binding site. The density for the calcium ion is very strong, displayed as blue mesh at the 20σ threshold. (**F**) Topology diagram of the CRD domain. (**G**) Calcium binding site in calmodulin (PDB ID: 1cll). (**H**) Sequence alignment of the calcium binding segment in the CRD domain of RET from human (**h**), mouse (**m**), chicken (**c**) and *Drosophila* (**d**). Circles and triangles highlight residues coordinating the calcium ion with sidechains and backbone carbonyl, respectively.](elife-47650-fig2){#fig2}

Structure of CRD in RET {#s2-3}
-----------------------

Notably, CRD in RET adopts a new fold that does not show significant similarity to other proteins in the PDB database. This small globular domain is composed of three small 2-or 3-stranded β-sheets and two short helices, which are connected by extensive loops ([Figure 2E and F](#fig2){ref-type="fig"}). These structural elements are stapled together by seven disulfide bonds. Cys630 and Cys634 in the linker between CRD and the transmembrane region of RET have been shown to form another disulfide bond, but the corresponding density is not well-resolved in our cryo-EM maps ([@bib9]). There is a strong blob of density in a pocket surrounded by a number of conserved acidic residues in CRD, including Asp567, Glu574 and Asp584, as well as several backbone carbonyl groups ([Figure 2E and H](#fig2){ref-type="fig"}). The arrangement of the oxygen atoms around the site resembles closely the calcium binding site in calmodulin ([Figure 2G](#fig2){ref-type="fig"}). We therefore tentatively assign this as a new calcium binding site in RET.

The structure of the RET extracellular region provides a basis for understanding disease-causing mutations of some cysteine residues in RET-CRD. For example, mutations of Cys609, Cys611, Cys618, Cys620 and Cys634 cause MEN2A ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) ([@bib40]; [@bib41]). These cysteine residues sit either at the periphery of CRD or in the linker between CRD and the transmembrane region of RET ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Mutations of these residues may not dramatically affect the folding or cell surface localization of RET, but leave one unpaired cysteine residue at the periphery of the protein, which can subsequently induce ligand-independent dimerization and constitutive activation of RET by forming an inter-chain disulfide bond ([@bib9]; [@bib28]). On the other hand, loss-of-function mutations throughout the RET extracellular region have been associated with Hirschsprung's disease ([@bib15]; [@bib44]; [@bib24]). Many of these mutations are distributed in the core of the protein, the co-receptor binding site or the calcium binding sites, thus likely affecting the stability or co-receptor binding of RET ([@bib35]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

Inter-subunit interactions in the RET ternary complexes {#s2-4}
-------------------------------------------------------

In all of the four ternary complex structures, the ligands use the convex face formed mostly by the two 'finger' loops to bind to the second domain (D2) of their respective co-receptors, similar to those shown by the previously determined X-ray structures of the ligand/co-receptor complexes ([@bib22]; [@bib47]; [@bib60]; [@bib43]); therefore, we will not describe the ligand/co-receptors interface in detail here.

RET makes contacts with the co-receptors and ligands by its N-terminal and C-terminal domains, respectively. The D3 domain of the co-receptors forms bipartite interfaces (denoted as interface I and II) with the N-terminal portion of the RET C-clamp in all of our reconstructions, although the detailed interactions are different in each ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A, C and E](#fig3s1){ref-type="fig"}). In the GDF15/GFRAL/RET complex, interface I is formed between a helix-loop-helix-loop motif (residues 246--265) in the D3 domain of GFRAL and the concave surface on CLD1 and CLD2 in RET ([Figure 3A](#fig3){ref-type="fig"}). The interface includes Trp37, Ala35, Thr120, Tyr146 and Thr170 from RET, Lys251, Thr261 and Ser263 from GFRAL. Interface II is made between a short loop (residues 295--299) in GFRAL and the CLD2-CLD3 junction near the calcium binding sites ([Figure 3A](#fig3){ref-type="fig"}). The segments in GFRα1, GFRα2 and GFRα3 corresponding to the helix-loop-helix-loop motif in GFRAL are much shorter and adopt extended loop conformations ([Figure 3---figure supplement 1A, C and E](#fig3s1){ref-type="fig"}). As a result, interfaces I in GFRα1/RET, GFRα2/RET and GFRα3/RET are much smaller (buried surface areas less than 700 Å^2^) and likely weaker than that in GFRAL/RET (buried surface area \~ 1500 Å^2^). Interfaces II of GFRα1, GFRα2 and GFRα3 with RET (buried surface areas \~ 730--1010 Å^2^) however are more extensive than that in GFRAL/RET (buried surface areas \~ 680 Å^2^), which may partially compensate for their weaker interfaces I. The D1 domain of the co-receptors is invisible in the 3D reconstructions of GDF15/GFRAL/RET, GDNF/GFRα1/RET, and ARTN/GFRα3/RET, suggesting that it is not involved in the binding to either RET or the ligands in these three complexes. In contrast, the D1 domain of GFRα2 is resolved in the cryo-EM map of the NRTN/GFRα2/RET complex, and packs closely with the D3 domain as seen in the crystal structure of the NRTN/GFRα2 complex ([@bib47]). The D1 domain of GFRα2 makes a few contacts with RET-CLD1, which may help stabilize the ternary complex.

![Binding interfaces in the GDF15/GFRAL/RET complex.\
(**A**) Interface between RET and GFRAL. An overall view of the complex structure is shown in the middle as a reference. (**B**) Interface between RET-CRD and GDF15. (**C**) Pull-down assays for the GDF15/GFRAL/RET ternary complex. Strep-tagged GFRAL bound to Streptavidin-conjugated beads was used to pull down GDF15 and RET. Streptavidin beads without Strep-GFRAL bound served as negative control. Mutations in either GFRAL or GDF15 abolish binding of RET. The results shown are representative of three biological repeats. (**D**) GDF15-induced ERK phosphorylation in HEK293 cells expressing full-length myc-tagged RET and GFRAL. Cells were treated with GDF15 at 10 nM for 15 min. ERK phosphorylation levels (pERK) were assessed by western blot. Expression levels of RET and GFRAL were monitored by anti-myc western blot. The results shown are representative of three biological repeats.](elife-47650-fig3){#fig3}

At the C-terminal portion of the RET C-clamp, RET-CRD interacts directly with the concave surface of the finger loops in the ligands, opposite to the side that binds the co-receptors ([Figure 3B](#fig3){ref-type="fig"}). As a result, the finger loops in the ligands appear to wedge between RET-CRD and the co-receptors. In the GDF15/GFRAL/RET complex, GDF15 embraces the surface formed by strands β3--7 along with several inter-strand loops in RET-CRD, through mainly hydrophobic interactions, burying Trp228, Met253 and Tyr297 in GDF15 and Ile551, Val591, Gly593, Tyr606 and Phe619 of CRD ([Figure 3B](#fig3){ref-type="fig"}). The interface also contains polar residues, such as Gln247 and Gln256 in GDF15. Similar ligand/CRD interfaces are formed in the other three ternary complexes ([Figure 3---figure supplement 1B, D and F](#fig3s1){ref-type="fig"}).

The simultaneous binding of RET to both the ligand and co-receptor explains the cooperativity in the formation of the ternary complexes, while neither the ligand nor co-receptor alone is sufficient for activation of RET ([@bib52]). To confirm the binding mode as shown in our structures, we introduced a T261R mutations in GFRAL to disrupt its interface I with RET. Our pull-down assay results showed that wild-type GFRAL was able to pull down RET and GDF15 simultaneously, indicating the formation of the ternary complex ([Figure 3C](#fig3){ref-type="fig"}). In contrast, the T261R mutant of GFRAL failed to support the formation of the GDF15/GFRAL/RET ternary complex ([Figure 3C](#fig3){ref-type="fig"}). Similarly, the mutations W228E and Y297E in GDF15, which target the interaction with RET-CRD, also abolished the formation of the ternary complex ([Figure 3C](#fig3){ref-type="fig"}). Furthermore, we examined the effects of these mutations on RET signaling by monitoring ERK phosphorylation in cells. Treatment of cells stably expressing both RET and GFRAL with wild-type GDF15 induced robust phosphorylation of ERK ([Figure 3D](#fig3){ref-type="fig"}). However, the W228E and Y297E mutations in GDF15 led to dramatically decreased phosphorylation of ERK ([Figure 3D](#fig3){ref-type="fig"}). Similarly, cells expressing wild-type RET but the T261R mutant of GFRAL showed lower levels of ERK phosphorylation when stimulated with wild-type GDF15 ([Figure 3D](#fig3){ref-type="fig"}). These results together confirm that the interfaces as seen in the structure are important for the formation of the GDF15/GFRAL/RET ternary complex as well as the activation of RET in cells.

Activation mechanism of RET {#s2-5}
---------------------------

In all of the four ternary complex structures, the ligand dimer directly interacts with the two CRDs from the two RET molecules and thereby bring them into close proximity. In addition, clear but relatively weak cryo-EM densities at the bottom faces of the ligands were observed for the linker between CRD and the transmembrane region of RET ([Figure 1---figure supplement 5A and B](#fig1s5){ref-type="fig"}). These observations suggest that the two copies of the linker converge near the plasma membrane. This configuration of the two RET molecules is poised to induce the dimerization of the transmembrane region and intracellular kinase domain, leading to cross-autophosphorylation of RET and subsequent activation of the downstream signaling cascades. Therefore, all the ligand/co-receptor pairs use the same general mechanism to activate RET. However, there are large differences in the angle between the two wings of the batwing-shaped complexes ([Figure 1B](#fig1){ref-type="fig"}), which mainly originate from the different conformations of the ligand dimers and their different interfaces with the co-receptors as noted previously ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}) ([@bib22]; [@bib47]; [@bib43]). This angle in the GDF15/GFRAL/RET complex (\~60°) is much more acute than that in the complexes of GDNF/GFRα1/RET (130°), NRTN/GFRα2/RET (105°) and ARTN/GFRα3/RET (108°) ([Figure 1B](#fig1){ref-type="fig"}). Associated with this angular variation, the distances between two CRDs in the complexes also differ to some extent. It is appealing to speculate that the differences in the angle and distance between the two RET molecules in the complexes may provide a mechanism in defining RET signaling specificity, which could potentially allow the five different ligands of RET to generate distinct signaling outputs from the same but versatile receptor.

RET can form higher-order oligomeric complexes {#s2-6}
----------------------------------------------

Surprisingly, some 2D class averages of the NRTN/GFRα2/RET and ARTN/GFRα3/RET complexes appear to be larger than the 2:2:2 complexes. With further 3D classification for the dataset of the NRTN/GFRα2/RET complex, we identified one class showing two 2:2:2 complexes arranged in a staggered fashion to form a 4:4:4 complex that resembles a four-bladed propeller. Subsequent 3D refinement yielded a map at 4.3 Å resolution, allowing us to build a complete model of the 4:4:4 complex by rigid-body fitting the atomic models of the protein components into cryo-EM map ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Video 1](#video1){ref-type="video"}). We performed the same image processing procedure for the dataset of the ARTN/GFRα3/RET complex, but the 3D reconstruction failed due to inadequate number of particles.

![Higher-order oligomerization of the NRTN/GFRα2/RET complex.\
(**A**) Refined map of the 4:4:4 NRTN/GFRα2/RET complex. (**B**) Atomic model of the 4:4:4 NRTN/GFRα2/RET complex shown in the surface representation. (**C**) Distance of the four RET molecules in the 4:4:4 complex to the plasma membrane. The gray box represents the plasma membrane. NRTN and GFRα2 are rendered semi-transparent to clearly show the position of the four RET molecules relative to the membrane. (**D**) Detailed view of the new interface between NRTN and RET that mediate the formation of the 4:4:4 complex. The view is expanded from the boxed region in the left panel of (**B**). (**E**) 3D class averages of the NRTN(WT)/GFRα2/RET and NRTN(R101E/R155E)/GFRα2/RET complexes. Wild-type NRTN formed complexes with RET and GFRα2 larger than the 2:2:2 stoichiometry, which were eliminated by the R101E/R155E mutation.](elife-47650-fig4){#fig4}

###### The assembly of the NRTN/GFRα2/RET 2:2:2 and 4:4:4 complexes.

10.7554/eLife.47650.015

Simple modeling of the 4:4:4 NRTN/GFRα2/RET complex on the surface of the plasma membrane shows that the distances of the four RET molecules to the membrane surface are different, due to a relative rotation of \~ 50° between the two 2:2:2 complexes ([Figure 4C](#fig4){ref-type="fig"}). As shown in [Figure 4C](#fig4){ref-type="fig"}, the distance between the end of the CRD in the two centrally located RET molecules (RET1 and RET2') and the membrane is \~ 35 Å, whereas that of the two peripheral RET molecules (RET2 and RET1') is \~ 15 Å. The linker (residues 623--636) between the last residue in RET-CRD and the N-terminus of transmembrane region is 14-residue long, but its linear span is shortened by the disulfide linkage between Cys630 and Cys634 to approximately equivalent to a 11-residue linker. This linker can readily bridge the 15 Å distance for the peripheral RET2 and RET1', but may be stretched to some extent in order to span the 35 Å distance for the central RET1 and RET2'. These analyses together suggest that the 4:4:4 complex can be formed by full-length RET on the cell surface, but it may display preference for membrane areas with a positive curvature.

The 4:4:4 NRTN/GFRα2/RET complex is mediated by a novel interface, formed between the protruding 'elbow' at the CLD4-CRD junction of RET and the convex face of NRTN near the GFRα2-binding site ([Figure 4D](#fig4){ref-type="fig"}). Particularly, the loop connecting CLD4 and CRD (residues 507--513) in RET makes a number of interactions with the surface of the major β-sheet in NRTN. Several charged residues in NTRN, including Arg101, Arg106, Glu107, Arg128, and Arg155, contribute to the interaction. We introduced an R101E/R155E double mutation to NRTN, and imaged the NRTN(R101E/R155E)/GFRα2/RET complex with cryo-EM. 3D classification result of this mutant complex clearly showed that the double mutations in NRTN exclusively abolished the formation of the 4:4:4 complex, but not the 2:2:2 complex, verifying that the novel NRTN/RET interface is responsible merely for the formation of the higher-order oligomer ([Figure 4E](#fig4){ref-type="fig"}).

In the 4:4:4 NRTN/GFRα2/RET complex, two of the RET molecules (RET1 and RET2' in [Figure 4](#fig4){ref-type="fig"}) are sandwiched between the two wings of the adjacent 2:2:2 complex. This configuration is only compatible with the structures of the NRTN/GFRα2/RET, GDNF/GFRα1/RET and ARTN/GFRα3/RET complexes where the angle between the two wings is large ([Figure 1B](#fig1){ref-type="fig"}). The angle between the two wings in the GDF15/GFRAL/RET complex is however much tighter, and therefore cannot accommodate the third RET molecule for the formation of the 4:4:4 complex. Indeed, no class averages of the 4:4:4 complex can be identified in the cryo-EM dataset of the GDF15/GFRAL/RET complex. Thus, assembling distinct signaling complexes of different oligomeric states may be a mechanism for the five ligands of RET to trigger distinct signaling outcomes through the same receptor. This difference seems to be in line with the fact that the signaling of the GDF15/GFRAL/RET complex is mostly involved in regulating metabolic responses, whereas the other RET complexes control cell growth, proliferation and survival.

Higher-order oligomerization regulates RET - endocytosis {#s2-7}
--------------------------------------------------------

Ligand-induced RET internalization through clathrin-mediated endocytosis plays a role in regulating signaling ([@bib10]; [@bib46]; [@bib45]). We speculated that the potential preference of the 4:4:4 NRTN/GFRα2/RET complex for positive membrane curvature mentioned above might impede its entrance to clathrin-coated pits, which have negative membrane curvature. It has been shown that the geometry and size of proteins can regulate vesicle secretion or endocytosis by changing the curvature of membrane, through mechanisms that are distinct from the membrane-bending effects of the BAR domains ([@bib11]; [@bib55]). To examine the effect of the 4:4:4 complex on RET endocytosis, we treated COS7 cells stably expressing full length RET and GFRα2 with fluorescence-labeled NRTN and monitored its endocytosis. The results showed that most wild-type NRTN remained on the cell surface as long as 15 min ([Figure 5A](#fig5){ref-type="fig"}). Very few intracellular puncta of NRTN were formed and co-localized with the early endosome marker EEA1 (early endosome antigen 1) ([Figure 5A](#fig5){ref-type="fig"}). In contrast, the NRTN(R101E/R155E) mutant were internalized quickly and formed many puncta co-localizing with EEA1 at the 5 min time point, which progressed to higher levels at 10 and 15 min ([Figure 5A](#fig5){ref-type="fig"}). For comparison, we carried out similar experiments for the GDF15/GFRAL/RET complex, which does not form higher-order oligomers. GDF15 underwent quick internalization, even faster than the NRTN(R101E/R155E) mutant ([Figure 5A](#fig5){ref-type="fig"}). We used the Pearson's correlation coefficient between the ligands and EEA1 as a quantitative indicator of the internalization of NRTN and GDF15 ([@bib34]). The quantification results show that the colocalization of wild-type NRTN with EEA1 remained at low levels at all of the three time points ([Figure 5B](#fig5){ref-type="fig"}). The NRTN(R101E/R155E) mutant displayed significantly higher levels of co-localization with EEA1, but lower than that of GDF15 ([Figure 5B](#fig5){ref-type="fig"}). These results together support the idea that the different oligomeric states of RET induced by the ligands can regulate the internalization. The slower endocytosis of the 4:4:4 NRTN/GFRα2/RET complex allows it to maintain the active state on the cell surface for a longer period of time, which may lead to distinct signaling outcomes as compared with the GDF15/GFRAL/RET complex that undergoes fast endocytosis.

![The 4:4:4 NRTN/GFRα2/RET complex delays RET endocytosis.\
(**A**) Endocytosis of the NRTN/GFRα2/RET and GDF15/GFRAL/RET complexes. Fluorescently labeled NRTN (wild-type or the R101E/R155E mutant) and GDF15 were incubated with COS7 cells expressing GFRα2/RET and GFRAL/RET, respectively, and imaged at indicated time points. EEA1 were immuno-stained to serve as an early endosome marker. (**B**) Quantification of the colocalization of NRTN wild-type, the R101E/R155E mutant and GDF15 with EEA1. Pearson's correction coefficients between the ligands and EEA1 were calculated for 35 cells in each group from two biological repeats. Each dot in the scatter plot represent one cell. The bars represent mean and standard deviation. P-values were calculated using the two-tailed Welch's t-test. \*\*\*\*p\<0.0001.\
10.7554/eLife.47650.017Figure 5---source data 1.Source data for [Figure 5B](#fig5){ref-type="fig"}.](elife-47650-fig5){#fig5}

Oligomerization of RET in the apo-state {#s2-8}
---------------------------------------

Some RTKs such as the epidermal growth factor receptor (EGFR), insulin-like growth factor receptor and insulin receptor ([@bib26]; [@bib32]) can form inactive dimers on the cell surface in the absence of ligand. Using analytical ultracentrifugation (AUC), we found that the extracellular region of apo-RET exhibits an intrinsic ability to oligomerize, existing in an equilibrium favoring the monomeric (4.8 S) form at the concentrations used, but evincing higher-order oligomers ranging from dimers (ca. 8 S) to perhaps tetramers or pentamers (13.5 S) ([Figure 6E](#fig6){ref-type="fig"}). This solution behavior comports with the appearance in apo-RET cryo-EM micrographs of elongated entities that were clearly larger than monomeric apo-RET (2D class averages are shown in [Figure 6D](#fig6){ref-type="fig"}). We were unable to determine the structures of these oligomers due to conformational heterogeneity. Interestingly, a crystallographic dimer of the CLD1-2 domains of RET has been reported previously ([Figure 6A](#fig6){ref-type="fig"}) ([@bib29]). We constructed a dimer of the full-length extracellular region of RET by superimposing two protomers of our RET model with the CLD1-2 crystallographic dimer, which resembles some of the 2D class averages ([Figure 6B and D](#fig6){ref-type="fig"}). This dimer model is further supported by the AUC results showing that a double mutation of Arg77 and Arg144 in the dimer interface abolished the oligomerization of the RET extracellular region ([Figure 6E](#fig6){ref-type="fig"}). In this ligand-free RET dimer model, the C-termini of the two CRD domains point to the same direction, consistent with their connection to the transmembrane region of RET expressed on the cell surface. However, the two CRDs in this dimer are placed far apart (\~120 Å), suggesting that it is in an inactive state of RET, because it imposes a large spatial separation of the two kinase domains that is unfavorable for cross-phosphorylation. The interface of the apo-RET dimer partially overlaps with the binding interface for the co-receptors ([Figure 6C](#fig6){ref-type="fig"}). Therefore, binding of a co-receptor to RET can both disrupt the inactive dimer and facilitate the ligand/RET interaction, eventually leading to the active dimer conformation of RET as seen in the structures of the ternary complexes.

![Ligand-independent dimerization of RET.\
(**A**) The dimer of RET-CLD1/CLD2 in a previously reported crystal structure (PDB ID: 2X2U) (**B**) The dimeric model of the full-length extracellular region of RET in the apo-state based on the dimer in (**A**). (**C**) The co-receptor binding interface overlaps with the apo-RET dimer interface. The two protomers in the RET dimer are shown in surface (cyan) and cartoon (blue) representations, respectively. GFRAL (green) bound to RET in cyan clashes with RET in blue, suggesting that binding of GFRAL can disrupt the dimer of apo-RET. (**D**) 2D class averages of RET in the apo-state. (**E**), Analysis of the oligomerization state of the apo-RET extracellular region by AUC. The peak with the sedimentation coefficient of 4.8 S corresponds to the RET monomer. Wild-type RET also contains another species with the sedimentation coefficient of \~ 7--9 S, suggesting higher-order oligomerization. The R77E/R144E mutant ran predominately as a monomer.](elife-47650-fig6){#fig6}

Discussion {#s3}
==========

Based on our structural analyses and previous studies, we propose a multi-state model for the regulation of RET signaling ([Figure 7](#fig7){ref-type="fig"}). This overall model and the structural details revealed by our cryo-EM structures provide a basis for understanding many mutations in RET that are associated with human diseases. The batwing-shaped dimeric complexes is the common mechanism for RET activation by the ligands and their respective co-receptors, while using quite different atomic interaction for the formation of the complex. The precise role of the apo-dimer of RET is not clear at present. It may help keep the kinase from cross-phosphorylation in the absence of the ligand. On the other hand, the existing dimer of RET on the cell membrane may facilitate the ligand-induced activation, as it enables a simple switch from the inactive to the active dimer as seen in some other RTKs such as EGFR and the insulin receptor ([@bib26]; [@bib32]). The formation of the higher-order oligomer of the NRTN/GFRα2/RET complex suggests an unanticipated novel layer of regulation for RET. Our data suggest that the formation of the 4:4:4 NRTN/GFRα2/RET complex delays RET endocytosis, likely leading to more sustained signaling. Along this line, previous studies have shown that RET endocytosis regulates both the duration and choice of pathway of signaling ([@bib46]; [@bib45]). NRTN mutations have been associated with Hirschsprung's disease, implicating that the NRTN-induced signaling of RET plays a role in the growth or guidance of enteric ganglia ([@bib12]; [@bib18]). The high-order NRTN/GFRα2/RET complex may be a mechanism to maintain sustained signal of RET required for these functions.

![A multi-state model of RET regulation on the cell surface.\
RET, the co-receptor and ligand are colored cyan, green and yellow, respectively. 'Y' and 'P' represent unphosphorylated and phosphorylated tyrosine residues, respectively.](elife-47650-fig7){#fig7}

Our analyses suggest that the formation of the high-order oligomeric complex is a specialized function of a subset of ligands of RET, as GDF15 and GFRAL cannot form similar 4:4:4 complex with RET because of the tight angle between the two wings in the dimeric complex. Therefore, while the batwing-shaped dimeric complex serves as the common basis for RET activation by all the ligands, the variations in the angle between the two wings enable different ligands to induce different signaling complexes of RET. This mechanism is reminiscent of the 'biased agonism' paradigm that is well-established for G-protein-coupled receptors (GPCRs), where multiple ligands of the same receptor can preferentially activate different downstream signaling pathways by inducing distinct activation kinetics or conformations of the receptor ([@bib59]). Recent studies have shown that some single-pass transmembrane receptors such as interferon-^γ^ receptor and the erythropoietin receptor are also able to mediate biased signaling for certain ligands ([@bib27]; [@bib36]). It is possible that the differences in endocytosis between the 2:2:2 versus 4:4:4 complexes of RET enable biased signaling and ultimately lead to profoundly different biological effects in vivo. In line with this idea, a recent study has shown that different ligands of EGFR, while inducing structurally similar active dimers of EGFR, can drive either cell proliferation or differentiation depending on the kinetic stability of the EGFR dimer ([@bib20]). In addition to different signaling kinetics, the 4:4:4 complex of RET may signal through unique downstream effectors that the 2:2:2 complex cannot bind. The distinct signaling pathways triggered by different ligands through RET may allow it to control the diverse biological processes such as development and appetite under different contexts.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                          Designation                                                           Source or\                  Identifiers                                                                  Additional\
  or resource                                                                                                            reference                                                                                                information
  ------------------------------------------------ --------------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  Antibody                                         Mouse monoclonal anti-Myc tag                                         Cell Signaling Technology   Cat\# 2276S; RRID: [AB_331783](https://scicrunch.org/resolver/AB_331783)     Dilution 1:1000

  Antibody                                         Rabbit monoclonal anti-p44/42 MAPK (Erk1/2)                           Cell Signaling Technology   Cat\# 4695; RRID:[AB_390779](https://scicrunch.org/resolver/AB_390779)       Dilution 1:1000

  Antibody                                         Rabbit monoclonal anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)   Cell Signaling Technology   Cat\# 4370; RRID: [AB_2315112](https://scicrunch.org/resolver/AB_2315112)    Dilution 1:1000

  Antibody                                         Rabbit monoclonal anti-EEA1(C45B10)                                   Cell Signaling Technology   Cat\# 3288; RRID:[AB_2096811](https://scicrunch.org/resolver/AB_2096811)     Dilution 1:1000

  Antibody                                         Goat anti-Mouse IgG H and L (HRP)                                     Invitrogen                  Cat\# 31430                                                                  Dilution 1:1000

  Antibody                                         Goat anti-Rabbit IgG H and L (HRP)                                    Abcam                       Cat\# ab6721; RRID:[AB_955447](https://scicrunch.org/resolver/AB_955447)     Dilution 1:1000

  Antibody                                         Goat anti-Rabbit IgG H and L (Alexa Fluor 488)                        Invitrogen                  Cat\# A-11034                                                                Dilution 1:1000

  Cell line (*Homo sapiens*)                       FreeStyle 293 F                                                       Invitrogen                  Cat\#R79007                                                                  

  Cell line (*Homo sapiens*)                       HEK293S GnTI-                                                         ATCC                        Cat\#CRL-3022; RRID:[CVCL_A785](https://scicrunch.org/resolver/CVCL_A785)    

  Cell line (*Homo sapiens*)                       HEK293                                                                ATCC                        Cat\# PTA-4488, RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)   

  Cell line (*Homo sapiens*)                       HEK293T                                                               ATCC                        Cat\#CRL-3216; RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)    

  Cell line (*Cercopithecus aethiops*)             COS-7                                                                 ATCC                        Cat\# CRL-1651, RRID:[CVCL_0224](https://scicrunch.org/resolver/CVCL_0224)   

  Strain, strain background (*Escherichia coli*)   *E. coli* BL21(DE3)                                                   New England Biolabs         Cat\# C2527                                                                  

  Strain, strain background (*Escherichia coli*)   XL10-Gold Ultracompetent Cells                                        Agilent                     Cat\# 200315                                                                 

  Strain, strain background (*Escherichia coli*)   MAX Efficiency DH10Bac Competent Cells                                Invitrogen                  Cat\# 10361012                                                               

  Chemical compound, drug                          isopropyl b-D-thiogalatopyranoside (IPTG)                             Fisher Scientific           Cat\# BP1620-10                                                              

  Chemical compound, drug                          Imidazole                                                             Sigma-Aldrich               Cat\# I5513                                                                  

  Chemical compound, drug                          L-Arginine                                                            Sigma-Aldrich               Cat\# A5006                                                                  

  Chemical compound, drug                          L(-)-Glutathione, oxidized                                            ACROS Organics              Cat\# AC320220050                                                            

  Chemical compound, drug                          Guanidine-HCl                                                         Thermo Scientific           Cat\# 24110                                                                  

  Chemical compound, drug                          L-Glutathione reduced                                                 Sigma-Aldrich               Cat\# G4251                                                                  

  Chemical compound, drug                          Urea                                                                  RPI                         Cat\# U20200                                                                 

  Chemical compound, drug                          Puromycin                                                             InvivoGen                   Cat\# ant-pr-1                                                               

  Chemical Compound, drug                          Blasticidin                                                           InvivoGen                   Cat\# ant-bl-1                                                               

  Chemical compound, drug                          Antibiotic Antimycotic Solution (100×)                                Sigma-Aldrich               Cat\# A5955                                                                  

  Chemical compound, drug                          Cellfectin II Reagent                                                 Gibco                       Cat\# 10362100                                                               

  Chemical compound, drug                          Sodium Butyrate                                                       Sigma-Aldrich               Cat\# 303410                                                                 

  Chemical compound, drug                          Halt Protease and Phosphatase Inhibitor Cocktail (100X)               Thermo Scientific           Cat\# 78442                                                                  

  Chemical compound, drug                          SuperSignal West Dura Extended Duration Substrate                     Thermo Scientific           Cat\# 34075                                                                  

  Chemical compound, drug                          DAPI (4\',6-Diamidino-2-Phenylindole, Dihydrochloride)                Invitrogen                  Cat\# D1306                                                                  

  Chemical compound, drug                          Alexa Fluor 555 NHS Ester                                             Invitrogen                  Cat\# A20009                                                                 

  Transfected construct (*Homo sapiens*)           pEZT-BM vector                                                        Ryan Hibbs Lab              Addgene plasmid \# 74099                                                     

  Transfected construct (*Homo sapiens*)           pEZT-RET-ECD-His                                                      This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Homo sapiens*)           pEZT-GFRAL-ECD-His                                                    This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Homo sapiens*)           pEZT-GFRA1-ECD-His                                                    This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Homo sapiens*)           pEZT-GFRA2-ECD-His                                                    This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Homo sapiens*)           pEZT-GFRA3-ECD-His                                                    This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression and purification

  Transfected construct (*Escherichia coli*)       pET-28a vector                                                        Novagen                     Millipore Cat\# 69864                                                        

  Transfected construct (*Escherichia coli*)       pET-15b vector                                                        Novagen                     Millipore Cat\# 69661                                                        

  Transfected construct (*Escherichia coli*)       pET-28a-GDF15-WT                                                      This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression and purification

  Transfected construct (*Escherichia coli*)       pET-28a-GDF15-W228E                                                   This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Escherichia coli*)       pET-28a-GDF15-Y297E                                                   This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression and purification

  Transfected construct (*Escherichia coli*)       pET-28a-sumo-NRTN-WT                                                  This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Escherichia coli*)       pET-28a-sumo-NRTN-R101E/R155E                                         This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Escherichia coli*)       pET-15b-GDNF-WT                                                       This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Escherichia coli*)       pET-28a-sumo- ARTN-WT                                                 This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Protein expression\
                                                                                                                                                                                                                                  and purification

  Transfected construct (*Homo sapiens*)           pLVX-IRES-Puro                                                        Clontech                    Cat\#632183                                                                  

  Transfected construct (*Homo sapiens*)           pLVX-RET-myc-IRES-Puro                                                This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Cell-based phosphorylation assay for RET

  Transfected construct (*Homo sapiens*)           pLVX-myc-GFRAL-WT-IRES-Blast                                          This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Cell-based\
                                                                                                                                                                                                                                  phosphorylation assay for RET

  Transfected construct (*Homo sapiens*)           pLVX-myc-GFRAL-T261R-IRES-Blast                                       This paper                                                                                               Materials and methods\
                                                                                                                                                                                                                                  subsection: Cell-based phosphorylation assay for RET

  Transfected construct (*Homo sapiens*)           pLVX-GFRA2-IRES-Blast                                                 This paper                                                                                               Materials and methods subsection: Cell-based\
                                                                                                                                                                                                                                  phosphorylation assay for RET

  Software, algorithm                              MotionCorr2                                                           [@bib65]                                                                                                 <http://msg.ucsf.edu/em/software/motioncor2.html>

  Software, algorithm                              GCTF                                                                  [@bib63]                                                                                                 [https://www.mrc-lmb.](https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/)\
                                                                                                                                                                                                                                  [cam.ac.uk/kzhang/Gctf/](https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/)

  Software, algorithm                              EMAN2                                                                 [@bib56]                                                                                                 [https://blake.bcm.edu/](https://blake.bcm.edu/emanwiki/EMAN2)\
                                                                                                                                                                                                                                  [emanwiki/EMAN2](https://blake.bcm.edu/emanwiki/EMAN2)

  Software, algorithm                              RELION                                                                [@bib49]                                                                                                 [https://www3.mrc-lmb.](https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Download_%26_install)\
                                                                                                                                                                                                                                  [cam.ac.uk/relion/index.php/Download\_%26_install](https://www3.mrc-lmb.cam.ac.uk/relion/index.php/Download_%26_install)

  Software, algorithm                              Coot                                                                  [@bib17]                                                                                                 [https://www2.mrc-lmb.cam.](https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/)\
                                                                                                                                                                                                                                  [ac.uk/personal/pemsley/coot/](https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/)

  Software, algorithm                              Phenix.refine                                                         [@bib2]                                                                                                  [https://www.phenix-online.](https://www.phenix-online.org/documentation/reference/refinement.html)\
                                                                                                                                                                                                                                  [org/documentation/reference/refinement.html](https://www.phenix-online.org/documentation/reference/refinement.html)

  Software, algorithm                              Graphpad prism 7.04                                                   Graphpad                                                                                                 [https://www.graphpad.com/](https://www.graphpad.com/scientific-software/prism/)\
                                                                                                                                                                                                                                  [scientific-software/prism/](https://www.graphpad.com/scientific-software/prism/)

  Software, algorithm                              Fiji                                                                  [@bib51]                                                                                                 <https://imagej.net/Fiji>

  Software, algorithm                              μManager                                                              Open Imaging                                                                                             <https://micro-manager.org/>

  Software, algorithm                              SEDFIT                                                                [@bib53]                                                                                                 [http://www.analyticalult](http://www.analyticalultracentrifugation.com/download.htm)\
                                                                                                                                                                                                                                  [racentrifugation.com/download.htm](http://www.analyticalultracentrifugation.com/download.htm)

  Software, algorithm                              REDATE                                                                [@bib64]                                                                                                 [http://biophysics.swmed.edu/](http://biophysics.swmed.edu/MBR/software.html)\
                                                                                                                                                                                                                                  [MBR/software.html](http://biophysics.swmed.edu/MBR/software.html)

  Software, algorithm                              GUSSI                                                                 [@bib8]                                                                                                  <http://biophysics.swmed.edu/MBR/software.html>

  Other                                            Ni Sepharose 6 Fast Flow                                              GE Healthcare               Cat\# 17531802                                                               

  Other                                            Strep-TactinXT Superflow                                              IBA Lifesciences            Cat\# 2-4010-025                                                             

  Other                                            Superdex 200 Increase 10/300 GL                                       GE Healthcare               Cat\# 28990944                                                               

  Other                                            Bolt 4--12% Bis-Tris Plus Gels, 10-well                               Invitrogen                  Cat\# NW04120BOX                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification {#s4-1}
-----------------------------------

All the protein sequence information can be found in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. The human Ret extracellular region (residues 1--635) and GFRα1 (residues 1--426) with a C-terminal His~8~-tag were sub-cloned into the pEZT-BM vector ([@bib38]). GFRAL (residues 20--352), GFRα2 (residues 24--362) and GFRα3 (residues 32--363) with the alkaline phosphatase (AP) signal peptide fused at the N-terminus and a C-terminal His~8~-tag were sub-cloned into the same vector. All of these proteins were expressed as secreted proteins in FreeStyle 293 F cells (Invitrogen, \#R79007) or HEK293S-GnTI^−^ cells (ATCC, \#CRL-3022) using the BacMam system following the standard protocol ([@bib38]). Briefly, bacmids carrying the target genes was generated by transforming the *E. coli* strain DH10BacY (Geneva Biotech). Baculoviruses were produced by transfecting Sf9 cells with bacmids. Baculoviruses (at 1:50 ratio) were used to infect FreeStyleTM 293 F or HEK293S-GnTI^−^ cells at the density of \~ 2 × 10^6^ cells/ml. Twelve hours later, 3 mM sodium butyrate was supplemented to boost protein expression. Culture medium was collected 3 days after infection by centrifugation at 3500 g at 4°C. Proteins were first captured by Ni^2+^-Sepharose 6 Fast Flow resin (GE healthcare) and then further purified by gel filtration chromatography with a Superdex S200 column (GE healthcare). All of the mutants were expressed and purified in the same manner as the respective wild type proteins. A double strep-tagged version of GFRAL was expressed and purified for the pull-down binding assays as well.

The genes coding the mature part of GDNF (residues 77-end) was inserted into pET-15b. The genes coding the mature part of GDF15 (residues 197-end) were codon-optimized and inserted into pET-28a, respectively. Genes coding the mature part of NRTN (residues 95-end) and ARTN (residues 108-end) were codon-optimized and inserted into a modified pET-28a vector encoding a SUMO-tag following the His~6~-tag. Proteins expressed from these vectors all contain an N-terminal His~6~-tag. Proteins were expressed in the *E. coli* strain BL21(DE3) as inclusion bodies and refolded according to the published protocol ([@bib62]), but using reduced glutathione and oxidized glutathione to help forming the disulfide bonds. Briefly, bacteria were cultured in 500 ml Terrific broth (TB) medium at 37°C. Protein expression was induced when the O.D. at 600 nm reached 2 by 1 mM IPTG for 4 hr at 37°C. Inclusion bodies were washed according to the published protocol and were dissolved in 10 ml 7 M Guanidine HCl, 0.15 M reduced glutathione, 30 mM Tris-HCL, 1 mM EDTA, pH 8.0. Solution was further clarified by centrifuge at 40,000 g for 30 min and 0.45 μm syringe filter. Solubilized inclusion bodies were added dropwise to 1 L refolding buffer containing 0.5 M L-arginine, pH 8.0, 0.6 mM oxidized glutathione with stirring for 16 hr at room temperature. The refold solution was then filtered by glass fiber prefilters (Minipore) and exchanged to a buffer containing 25 mM Tris-HCl, 200 mM NaCl, pH 8.0 with a Vivoflow 200 system (Sartorius). The refolded proteins were purified by a combination of Ni-NTA affinity and gel filtration chromatography. Urea at 3 M was added to the purification buffer to improve the solubility of all the GDNF family proteins. All of the purification steps were performed at 4°C. All of the mutants were expressed and purified in the same manners as the respective wild type proteins.

The RET protein was mixed with GDF15 protein and GFRAL protein at the molar ratio of 1:1:1 to form the ternary complex. The proteins mixture was incubated for half an hour before being further purified by gel filtration chromatography. In the gel filtration experiment, the superdex 200 increase 10/300 column was firstly equilibrated with two column volumes of buffer (10 mM Tris buffer with 150 mM NaCl and 1 mM CaCl~2~ (pH 7.4)) at 4°C.\~300 µl sample was injected into the column. A 96-Well plate was placed at the fraction collector for the sample collection. The peak containing the ternary complex was collected and concentrated to 1 mg/ml for cryo-EM analyses ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The GDNF/GFRα1/RET, NRTN/GFRα2/RET and ARTN/GFRα3/RET complexes were obtained with the same method ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Cell lines {#s4-2}
----------

293FT, Human embryonic kidney: from Invitrogen, identifier: R70007. HEK293 GNT^-^, Human embryonic kidney. from ATC, identifier: CRL-3022. HEK293, Human embryonic kidney. from ATC, identifier: PTA-4488. HEK293T, Human embryonic kidney. from ATC, identifier: CRL-3216. COS-7. from ATC, identifier: CRL-1651. *E. coli* BL21(DE3). from New England Biolabs, identifier: C2527. XL10-Gold Ultracompetent Cells. from Agilent, identifier: 200315. MAX Efficiency DH10Bac Competent Cells. from Invitrogen, identifier: 10361012. The identities of all these cell lines have been authenticated. The mycoplasma contamination testing was performed and shown to be negative.

EM data acquisition {#s4-3}
-------------------

All cryo-EM grids were prepared by applying 3 μl of protein samples (1 mg/ml) to glow-discharged Quantifoil R1.2/1.3 300-mesh gold holey carbon grids (Quantifoil, Micro Tools GmbH, Germany). Grids were blotted for 5.0 s under 100% humidity at 4°C before being plunged into liquid ethane using a Mark IV Vitrobot (FEI). Micrographs were acquired on a Titan Krios microscope (FEI) operated at 300 kV with a K2 Summit direct electron detector (Gatan), using a slit width of 20 eV on a GIF-Quantum energy filter. EPU software (FEI) was used for automated data collection following standard FEI procedure. A calibrated magnification of 46,730X was used for imaging, yielding a pixel size of 1.07 Å on images. The defocus range was set from −1.5 μm to −3 μm. Each micrograph was dose-fractionated to 30 frames under a dose rate of 4 e-/pixel/s, with a total exposure time of 15 s, resulting in a total dose of about 50 e^-^/Å^2^.

Image processing {#s4-4}
----------------

For all the four datasets of the different RET ternary complexes, the image processing was carried out with the same workflow, and the detailed data collection and processing statistic is summarized in [Table 1](#table1){ref-type="table"}. Motion correction was performed using the MotionCorr2 program ([@bib65]), and the CTF parameters of the micrographs were estimated using the GCTF program ([@bib63]). Initially,\~5000 particles were picked with EMAN2 from a few micrographs ([@bib56]). All other steps of image processing were performed using RELION ([@bib49]; [@bib48]). Class averages representing projections in different orientations selected from the initial 2D classification were used as templates for automatic particle picking from the full datasets. Extracted particles were binned three times and subjected to 2D classification. Particles from the classes with fine structural feature were selected for 3D classification. Approximately 20,000 particles were selected to generate the initial mode in RELION. Particles from the 3D classes showing good secondary structural features were selected and re-extracted into the original pixel size of 1.07 Å. 3D refinements with C2 symmetry imposed resulted in 3D reconstructions to relatively low resolution for all the 4 datasets of the different RET ternary complexes. The density for the outer edge of RET appeared blurred, suggesting relative swinging motions of the two wings in the complexes. To improve the resolution, we performed symmetry expansion and focused refinement as described previously ([@bib5]; [@bib66]; [@bib42]). To do so, all particles in the dataset were duplicated and rotated by 180° according to the C2 symmetry by using the 'relion_particle_symmetry_expand' command. The original and rotated particles were combined to form the symmetry expanded dataset. Subsequently, the density for one RET and one co-receptor from one wing was subtracted from the particles in the symmetry expanded dataset. These operations resulted in a new particle set representing one RET, one co-receptor and the ligand dimer from both the left and right wings of the original dataset. The modified particle set was subjected to another round of 3D refinement with a soft mask around one RET, one co-receptor and ligand dimer, leading to a markedly improved resolution for the entire single wing complex. For the NRTN/GFRα2/RET data, we performed a separate 3D refinement with 2-fold symmetry imposed for the particles corresponding to the 4:4:4 complex, resulting a map at 4.3 Å resolution.

10.7554/eLife.47650.020

###### Cryo-EM data collection and model statistics.

  --------------------------------------------------------------------------------------------------
                                   GDF15/GFRAL\   GDNF/GFRα1/RET   NRTN/GFRα2/RET   ARTN/GFRα3/RET
                                   /RET                                             
  -------------------------------- -------------- ---------------- ---------------- ----------------
  Data collection and processing                                                    

  Magnification                    46,730         46,730           46,730           46,730

  Voltage (kV)                     300            300              300              300

  Electron exposure (e^-^/Å^2^)    50             50               50               50

  Defocus range (µm)               1.6--3         1.6--3           1.6--3           1.6--3

  Pixel size (Å)                   1.07           1.07             1.07             1.07

  Final particle number            *520,480*      37,098           247,157          114,344

  Map resolution (Å)               3.7            4.4              3.4              3.5

  Map Sharpening *B* factor        −190           −200             −140             −140

  Model Refinement\                \              \                \                \
  Rms deviations\                  \              \                \                \
  Bonds (Å)\                       0.006\         0.005\           0.005\           0.007\
  Angles (°)\                      0.978\         0.994\           0.797\           1.040\
  Validation\                      \              \                \                \
  Molprobity score\                1.59\          2.02\            1.45\            1.73\
  Clashscore\                      4.43\          8.53\            2.74\            4.35\
  Rotamer outliers (%)\            0.12\          0.41\            0\               0.12\
  Ramachandran plot\               \              \                \                \
  Favored (%)\                     94.6\          89.5\            94.2\            91.1\
  Allowed (%)\                     5.3\           10.4\            5.8\             8.9\
  Outliers (%)                     0.1            0.1              0\               0\
  --------------------------------------------------------------------------------------------------

All resolutions were estimated by applying a soft mask around the protein density using the gold-standard Fourier shell correlation (FSC) = 0.143 criterion ([@bib50]). It worth mentioning that the resolution of the GDNF/GFRα1/RET complex estimated by the FSC between two half maps (4.4 Å) is not consistent with the one measured by the FSC between the map and model (7.5 Å), suggesting that the resolution of the cryo-EM map is overestimated, presumably due to the preferred orientation issue in this dataset. Nevertheless, the map with clearly resolved secondary structural features provides adequate quality for the rigid body docking and restrained refinement of the model. The symmetry expansion and focused refinement approaches failed to significantly improve the map quality of the GDNF/GFRα1/RET complex. Therefore, we only used the map refined with C2 symmetry imposed for the model building and refinement.

The datasets of the complexes contained a subset of particles of RET without the ligand or coreceptor bound. We obtained a 3D reconstruction of apo-RET by refinement of these particles in the GDF15/GFRAL/RET dataset by a procedure similar to that stated above. The resolution of this map is low, due to the small size of the protein. However, it clearly shows the C-clamp shape of apo-RET that is very similar to RET in the ternary complexes.

We also collected a dataset for the oligomeric peak of apo-RET, but could not obtain a reliable 3D reconstruction due to structural flexibility. Instead, we performed a 2D analysis for this data set showing features of the inhibitory dimer of apo-RET.

Model building and refinement {#s4-5}
-----------------------------

Model building of the GDF15/GFRAL/RET complex was initiated by docking the crystal structures of the GDF15/GFRAL complex (PDB ID: 5VZ4) ([@bib22]) and the CLD1/CDL2 domains of RET (PDB ID: 2X2U) ([@bib29]) into the high-resolution one-wing map from the focused refinement in the program Coot ([@bib17]). CLD3, CLD4 and CRD of RET are built de novo in Coot. While the D1 domain of GFRAL was present in the protein sample, it was completely disordered and invisible in the density map. Density at the bottom of the GDF15 dimer for the linker (Residues 623--635) between the CRD and transmembrane region of RET is weak but clearly visible when the map is contoured at lower levels ([Figure 1---figure supplement 5A](#fig1s5){ref-type="fig"}). This part was not included in the model because the map does not show enough features for reliable model building. The model containing the GDF15 dimer, one GFRAL and one RET was manually adjusted in Coot and refined against the map by using the real space refinement module with secondary structure and non-crystallographic symmetry restraints in the Phenix package ([@bib1]; [@bib2]). Model geometries were assessed by using Molprobity as a part of the Phenix validation tools and summarized in [Table 1](#table1){ref-type="table"}. The refined model was rotated by 180° according to the 2-fold symmetry in the GDF15 dimer. The two models were combined to construct the entire 2:2:2 GDF15/GFRAL/RET complex, which shows good agreement with the 3D reconstruction of the entire complex. The model building of the 2:2:2 complexes of NRTN/GFRα2/RET and ARTN/GFRα3/RET was initiated by docking the RET model refined above and the crystal structure of the NRTN/GFRα2 (PDB ID: 5MR4) ([@bib47]) and ARTN/GFRα3 complexes (PDB ID: 2GH0) ([@bib60]) into the one-wing map. The rest of the process was the same as that for the GDF15/GFRAL/RET complex. A model containing two 2:2:2 NRTN/GFRα2/RET complexes were built and refined based on the cryo-EM map of 4:4:4 NRTN/GFRα2/RET complex to generate the entire model of 4:4:4 NRTN/GFRα2/RET complex ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The density for the GDNF/GFRα1/RET complex was relatively poor, but sufficient for manual docking of the individual domains of RET, GFRα1 and the GDNF dimer (PDB ID: 3FUB) ([@bib43]). The entire 2:2:2 GDNF/GFRα1/RET complex was refined against the whole map in Phenix using the same methods as above but with tighter geometric restraints.

Analytical ultracentrifugation {#s4-6}
------------------------------

The sedimentation velocity centrifugation experiments were carried out for both of the two peaks of the RET extracellular region from gel filtration chromatography by using a Beckman Coulter Optima XL-I ultracentrifuge. The centrifugation buffer contained 20 mM HEPES pH 7.4, 300 mM NaCl, 4 mM CaCl~2~. Proteins (400 μL) at three different concentrations (O.D. at 280 nm of 0.8, 0.25, 0.08) were loaded into the 'sample' side of dual-sectored, charcoal-filled Epon centerpieces, while equal volumes of the centrifugation buffer were loaded into the 'reference' sectors. Sapphire windows were employed to sandwich the centerpieces. Filled cells were loaded into an An50Ti rotor and equilibrated at 20°C for about 2.5 hr under vacuum before centrifugation. Data were acquired at 50,000 rpm at 20°C via absorbance at 280 nm running overnight. Data were analyzed by using the *c*(*s*) methodology in the program SEDFIT ([@bib53]). A time-dilation factor was applied to the data using the program REDATE ([@bib64]). The program GUSSI was used to generate the all figures featuring *c*(*s*) distributions ([@bib8]).

Pull-down assay {#s4-7}
---------------

Streptavidin conjugated beads (IBA Lifesciences) (10 µl) are incubated with 2 µg GDF15 and 6 µg double strep-tagged GFRAL by head-to-head rotation in 650 µl binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl~2~) for 1 hr at 4°C. Beads were washed with 700 µl binding buffer for three times, and then incubated with12 µg Ret in 650 ul binding buffer for 1 hr at 4°C. Beads were further washed with 700 µl binding buffer for three times and subjected to SDS-PAGE analyses.

Cell-based phosphorylation assay for RET {#s4-8}
----------------------------------------

The coding sequence for full-length human RET with a C-terminal Myc-tag was inserted into the lentivirus vector pLVX-IRES-Puro with puromycin as the selection marker (Clontech). The coding sequence for human GFRAL (wild-type and the T261R mutant) and GFRα2 with a N-terminal Myc-tag were inserted into the lentivirus vector pLVX-IRES-Blast with blasticidin as the selection marker. HEK293 Cells stably expressing RET and GFRAL were selected with 2 µg/ml puromycin and 10 µg/ml blasticidin for 7 days. Cells were cultured in 6-well plates and then serum-starved for 12 hr before treatment with GDF15 wild-type and mutants at 10 nM for 15 min at 37°C. Cells were lysed in the lysis buffer containing 50 mM Tris pH7.5, 5 mM EDTA and 150 mM NaCl, 1% Triton X-100, and protease and phosphatase inhibitor cocktails (Invitrogen). Cleared lysates were resolved on 4--20% Tris-Glycine PAGE gels and subjected to western blot analyses. Images were acquired by using a ChemiDoc imaging system (Bio-Rad). The primary antibodies against Myc (cat. \#2276), ERK1/2 (cat. \#4695), phosphor-ERK1/2 (cat. \#4370) were purchased from Cell Signaling Technology.

Immuno-fluorescence imaging {#s4-9}
---------------------------

RET endocytosis was analyzed with a protocol similar to that used for plexin in a previous study ([@bib54]). Briefly, COS-7 cells stably expressing RET/GFRAL or RET/GFRα2 were seeded on coverslips in 6-well plates and cultured for 16 hr. Cells were washed with PBS three times, and then treated with Alexa Fluor-555 labeled GDF15 or NRTN at 15 nM for 5, 10 or 15 min. Cells were immediately put on ice, washed with ice-cold PBS buffer three times and fixed with 4% (w/v) paraformaldehyde (PFA) for 30 min at room temperature. Cells were permeabilized with 0.05% (w/v) saponin for 5 min and non-specific binding sites were blocked by a quenching buffer (0.01% (w/v) saponin, 2% (w/v) BSA, 0.1% (w/v) lysine in PBS, pH7.4) for 20 min. Cells were stained with rabbit anti-EEA1 antibody over night at 4°C and goat anti-rabbit secondary antibody for 1 hr at room temperature. Cells were imaged with a Plan Apo 60 × 1.4 objective (Nikon) on a spinning-disc confocal system built around a Ti-E Perfect Focus microscope (Nikon) with an EM camera (c9100-13; Hamamatsu) controlled by Micro-Manager software ([@bib14]). Excitation wavelengths used were 405 nm (for DAPI), 488 nm (for EEA1), 561 nm (for Alexa Fluor-555 labeled ligands) with the corresponding emission filters 460/50, 525/50 and 595/50, respectively. Confocal images were processed using the Fiji distribution of ImageJ ([@bib51]). A central slice from the stack of confocal images was chosen for calculating the Pearson's correlation coefficient (PCC) between EEA1 and NRTN or GDF15 by using the Coloc two plugin in Fiji. PCC values were calculated for individual cells defined as regions of interest. P-values were calculated using two-tailed Welch's t-test in Prism 7.04.
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Data availability {#s7}
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Cryo-EM maps and the corresponding models of RET/co-receptors/ligands complexes have been deposited in EMDB and PDB under the accession codes EMD-20572/EMD-20573/EMD-20575/EMD-20576/EMD-20577/EMD-20578/EMD-20579/EMD-20580 and 6Q2J/6Q2N/6Q2O/6Q2R/6Q2S, respectively. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 5.

The following datasets were generated:

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa2/NRTN extracellular complex. The 3D refinement was applied with C2 symmetry.Electron Microscopy Data BankEMD-20576

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa2/NRTN extracellular complex. The 3D refinement was focused on one of two halves with C1 symmetry applied.Electron Microscopy Data BankEMD-20577

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa2/NRTN extracellular complex in the tetrameric formElectron Microscopy Data BankEMD-20578

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa3/ARTN extracellular complex. The 3D refinement was applied with C2 symmetry.Electron Microscopy Data BankEMD-20579

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa3/ARTN extracellular complex. The 3D refinement was focused on one of two halves with C1 symmetry applied.Electron Microscopy Data BankEMD-20580

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the extracellular complex of RET/GFRAL/GDF15RCSB Protein Data Bank6Q2J

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa1/GDNF extracellular complexRCSB Protein Data Bank6Q2N

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa2/NRTN extracellular complex.RCSB Protein Data Bank6Q2O

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa2/NRTN extracellular complex in the tetrameric formRCSB Protein Data Bank6Q2R

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa3/ARTN extracellular complex.RCSB Protein Data Bank6Q2S

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRAL/GDF15 extracellular complex.Electron Microscopy Data BankEMD-20572

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRAL/GDF15 extracellular complex. The 3D refinement was focused on one of two halves with C1 symmetry applied.Electron Microscopy Data BankEMD-20573

JieLiGuijunShangYu-JuChenChadA BrautigamJenLiouXuewuZhangXiao-chenBai2019Cryo-EM structure of the RET/GFRa1/GDNF extracellular complexElectron Microscopy Data BankEMD-20575
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Cynthia Wolberger as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Daniel J Leahy (Reviewer \#2); Adrian Whitty (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Li et al., report 4 cryo-EM structures of the RET extracellular region (ECD) complexed with different co-receptors and ligands (GDNF/GFRa1. NTN/GFRa2, ART/GFRa3, and the recently reported GDF15/GFRaL). These structures represent the first views of complete RET ECD/co-receptor/ligand complexes and are highly revealing. The lack of a full structure of RET itself has so far hampered detailed structure-function studies on this important signaling receptor, and by elucidating the structures of RET and of these four RET/Ligand/Co-receptor complexes, this manuscript substantially advances our knowledge and understanding of how RET is activated -- with implications for the many other growth factor and cytokine receptors that interact with multiple ligands and/or co-receptors. One very interesting feature of this receptor system is the fact that the individual ligand/co-receptor complexes have significantly different geometries that lead to distinct dimeric arrangements/orientations in the structures summarized in Figure 1B of the manuscript. The authors describe the interactions between the components well, and validate the various ligand/receptor interactions reasonably with mutational studies. The structures seem to confirm the bipartite interactions previously inferred from lower resolution EM studies of GDNF/GFRa1 by McDonald\'s group, arguing that the CLDs of RET primarily interact with the co-receptor, but the CRD (for which the first structure is reported here) directly engages the ligand.

The observation of higher-order receptor clusters is potentially important, because there has been speculation in the literature that formation of higher-order complexes could be an important feature of many receptor signaling mechanisms -- but this has proven to be a difficult question to probe experimentally. Here, the authors observe a 4:4:4 (vs. 2:2:2) complex of NRTN/GFRa2/RET in their EM studies, and argue that mutations at the interface between the 2:2:2 subunits in the 4:4:4 complex result in an enhanced level of signaling and a depressed rate of endocytosis (see comments below). Interestingly, owing to the variable \"bat wing\" angles within the 2:2:2 complexes with different ligands, not all RET/GFRa/ligand complexes are compatible with formation of 4:4:4 complexes. Thus, the authors may have uncovered an interesting way for selective formation of higher-order receptor oligomers to modulate signaling responses. The authors also provide some evidence that the unbound RET extracellular domain may self-associate to form an inactive homodimer -- with the regions of RET that mediate this homotypic interaction indicating that binding of ligand/co-receptor would be expected to compete with RET homodimer formation.

One general criticism is that the authors do not really link their work to previous suggestions from the McDonald lab that the CRD is a major driver of dimerization -- although this is implied in the text (and in Figure 1---figure supplement 5A/B). Although the structural work is strong, and documents a variety of RT complexes with its ligands and their co-receptors, several functional aspects of the study are weak. Moreover, there is a surprising focus on some observations that are not well supported as being relevant -- at the cost of a better contextualization of the work in the field.

Essential revisions:

1\) Is there evidence in the literature for differential responses in the same cells to different RET/GFR ligands?

2\) In subsection "Higher-order oligomerization regulates RET signaling and endocytosis", the authors state that mutation of RET to block higher-order complex formation \"markedly reduced NRTN-induced ERK phosphorylation\", shown in Figure 5A. Based on the figure provided, I would say that the effect is much more subtle than this description implies. Unless the effect is more striking in the publication-quality figure, it is important that the authors include densitometry analysis and appropriate statistics on the three biological replicates to show that the effect is robust and reproducible.

3\) Similarly, the micrographs presented in the manuscript do not seem to show internalization of the mutated NTRN, despite what the EEA1 colocalization graph suggests. Where are the punctae for mutated NRTN? Perhaps it is a micrograph quality issue, but this is just not convincing. This further reduces the extent to which the section on higher-order oligomers is unconvincing, and needs significant additional experimental work and quantitation if the current conclusions are to stand.

4\) The authors note that the membrane-contacting termini of the four RET receptors in the higher-order RET tetrameric complex do not lie in the same plane. Based on this finding, they propose that these higher-order complexes favor regions of the membrane with high positive curvature. This conclusion is highly speculative, and feels like a throw-away explanation -- requiring much deeper analysis and stronger experimental support to be compelling. What degree of curvature would be required? Is it known that cell membrane regions exist that show this level of curvature? Are there any published data from studies on other systems that provide a precedent for this phenomenon? Are there other explanations for the geometry of the tetrameric complex if this one proves incorrect? If the authors prefer not to go more deeply into this question, they should instead just say that it is unclear exactly how the tetrameric matric contacts the membrane, with the notion that membrane curvature could be involved as one speculative possibility.

4\) The authors should indicate what methods were used to verify the identity, purity, and activity of the purified proteins.

5\) Some additional experimental details are required, in Materials and methods section, to truly make the work reproducible by other workers. This is an important issue because refolding the mature parts of GDNF-family proteins into the active form can be difficult, so it is important that the authors describe in detail how all proteins used in the study were cloned, expressed, refolded, and purified. In particular, for the cloning, expression and purification work, the authors should specify what are the modifications from the published protocol that they allude to in subsection "Protein expression and purification". They should also specify the volumes as well as the compositions of the buffers used for each step, etc. If any proteins required modifications to the protocol used for the other family members, these modifications should be specified. The sequences of all constructs should also be provided. The guide should be: what would another investigator need to know to follow precisely what the authors did and get it to work? Some of this detail can be relegated to Supplementary Information if required.

6\) The AUC data suggest protein aggregation. Did the authors undertake equilibrium studies to ask whether this is a normal reversible interaction? Its relevance is difficult to assess.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Cynthia Wolberger (Senior Editor), a Reviewing Editor, and three reviewers.

The reviewers feel the manuscript has been improved, but there are some remaining issues that need to be addressed before acceptance, as outlined below.

1\) Two of the reviewers remain unconvinced by the data on the effects of NRTN mutations on Erk activation in Figure 5A -- which is an important point concerning the functional relevance of higher-order Ret complexes. We recommend that these data be removed (and the conclusions adjusted accordingly), or else presented with proper description of statistical significance in a way that is standard for this type of experiment. Without demonstration of statistical significance, the data should not be included. If the figure is retained, a dose/response analysis should be included, since the mutations could simply be affecting binding affinity.

2\) The authors should include the procedure for the gel filtration experiments shown in new Figure 1---figure supplement 1, in Materials and methods section.

3\) Please label identify bands in Figure 1---figure supplement 1. If possible, it it would be desirable to show additional characterization data such as SDS-PAGE and analytical SEC chromatograms of each protein by itself, or MS data to show the intact mass of each protein.

10.7554/eLife.47650.051

Author response

> \[...\] One general criticism is that the authors do not really link their work to previous suggestions from the McDonald lab that the CRD is a major driver of dimerization -- although this is implied in the text (and in Figure 5---figure supplement 5A/B). Although the structural work is strong, and documents a variety of RT complexes with its ligands and their co-receptors, several functional aspects of the study are weak. Moreover, there is a surprising focus on some observations that are not well supported as being relevant -- at the cost of a better contextualization of the work in the field.

We have added one sentence in the Introduction to highlight the contributions of the McDonald paper regarding the role of the CRD in RET dimerization. We believe that the other concerns refer to the same points as some of the questions in the "essential revisions", which are answered below.

> Essential revisions:
>
> 1\) Is there evidence in the literature for differential responses in the same cells to different RET/GFR ligands?

We thank the reviewers for raising this important question. We didn't find any direct evidence showing that RET can respond differently to different ligands/co-receptors in the same type of cells. Actually, it has been known that GFRα1-3 show distinct spatial and temporal expression levels at different stages of embryonic development. GDNF/GFRα1/RET, NRTN/GFRα2/RET, and ARTN/GFRα3/RET signaling complexes have overlapping roles in neurodevelopment. Therefore, it is possible that, in the same type of cell, GDNF/GFRα1, NRTN/GFRα2, and ARTN/GFRα3 can trigger similar downstream cellular responses through RET. It also has been shown that there are alternative interactions between these three ligands and co-receptors. For instance, GFRα1, in addition to its prevalent partner GDNF, can interact with NRTN or ARTN to activate RET as well, further suggesting the redundancy of RET signaling. Consistently, the cryo-EM structures of GDNF/GFRα1/RET, NRTN/GFRα2/RET, and ARTN/GFRα3/RET complexes show similar architecture that the two RETs in each complex adopt very wide angles.

By contrast, the newly discovered GDF15/GFRAL pair can trigger metabolic responses and suppress the appetite through activating RET, distinct to the roles of GDNF/GFRα1/RET, NRTN/GFRα2/RET, and ARTN/GFRα3/RET, which are primarily involved in mitogenic pathway. On the other hand, both GFRAL and GFRαs have high expression levels in the hindbrain region; therefore, we speculated that GDF15/GFRAL and other ligands/co-receptors may trigger differential responses in cells in the hindbrain. The remarkable conformational differences of RET caused by different ligands/co-receptors (sharp angle verse wide angle; dimer verse tetramer) may provide a mechanism in defining RET signaling specificity, which could potentially allow generating distinct signaling outputs from the same receptor. Similar ideas have been proposed for the EGFR and TLR4 related signaling pathways (Freed et al., 2017; Piccinini et al., 2016). A sentence is added (subsection "RET can form higher-order oligomeric complexes") to briefly touch on this point.

> 2\) In subsection "Higher-order oligomerization regulates RET signaling and endocytosis", the authors state that mutation of RET to block higher-order complex formation \"markedly reduced NRTN-induced ERK phosphorylation\", shown in Figure 5A. Based on the figure provided, I would say that the effect is much more subtle than this description implies. Unless the effect is more striking in the publication-quality figure, it is important that the authors include densitometry analysis and appropriate statistics on the three biological replicates to show that the effect is robust and reproducible.

As suggested, the quantification results of the western blots are now included in the figure. To show the reproducibility of the results, we also included three biological repeats of the experiments in Figure 5---figure supplement 1. Due to the high levels of variability among different repeats, which is often the case in this type of western blots, we did not do averaging and p-value analyses. However, in the four repeats, the trend of higher phosphorylation levels induced by wild type NRTN compared to the R101E/R155E mutant is very clear. We also toned down the description in the manuscript by removing the word "markedly".

> 3\) Similarly, the micrographs presented in the manuscript do not seem to show internalization of the mutated NTRN, despite what the EEA1 colocalization graph suggests. Where are the punctae for mutated NRTN? Perhaps it is a micrograph quality issue, but this is just not convincing. This further reduces the extent to which the section on higher-order oligomers is unconvincing, and needs significant additional experimental work and quantitation if the current conclusions are to stand.

We apologize for the low quality images. We failed to notice that the figures were compressed by the server of *eLife*, which led to severely decreased quality of the images and obscured puncta. Puncta are clearly visible in our high-resolution original figure. We have provided the original micrographs in the revised submission. As shown in the high resolution image, most of the fluorescently labelled NRTN WT retain on the cellular membrane, but the NRTN mutant is internalized, and co-localized with EEA1, which supports our conclusion that the tetrameric RET complex reduces clathrin-mediated endocytosis.

> 4\) The authors note that the membrane-contacting termini of the four RET receptors in the higher-order RET tetrameric complex do not lie in the same plane. Based on this finding, they propose that these higher-order complexes favor regions of the membrane with high positive curvature. This conclusion is highly speculative, and feels like a throw-away explanation -- requiring much deeper analysis and stronger experimental support to be compelling. What degree of curvature would be required? Is it known that cell membrane regions exist that show this level of curvature? Are there any published data from studies on other systems that provide a precedent for this phenomenon? Are there other explanations for the geometry of the tetrameric complex if this one proves incorrect? If the authors prefer not to go more deeply into this question, they should instead just say that it is unclear exactly how the tetrameric matric contacts the membrane, with the notion that membrane curvature could be involved as one speculative possibility.

We thank th reviewers for this critical comment. We completely agree with this reviewer that we don't know for certain whether this tetrameric RET complex can alter membrane curvature or not. We therefore toned down this point as suggested.

There are indeed papers in the literature showing that the geometry and size of proteins can regulate vesicle secretion or endocytosis by changing the curvature of membrane, through mechanisms that are distinct from the membrane-bending effects of the BAR domains (Shurer et al., 2019; DeGroot, et al., 2018). We have now added a few sentences to describe these findings and cited these papers in the manuscript. We agree that, to establish the relationship between the RET higher order oligomerization and membrane curvature, we need to perform more in vivo experiments, particularly those involving single-molecule techniques. These experiments are beyond the scope of this particular paper, however.

> 4\) The authors should indicate what methods were used to verify the identity, purity, and activity of the purified proteins.

We used SEC and SDS-PAGE to verify the protein identity and purity. As shown in new Figure 1---figure supplement 1, the ligand/co-receptor/RET co-elute in the SEC, and appear in the earlier fractions, as compared with RET alone. The SDS-PAGE results show that there are no other contaminant proteins in these complexes. The earlier elution time and the multiple peaks of the NRTN/GFRa2/RET, ARTN/GFRa3/RET and GDNF/GFRa1/RET complexes suggest partial formation of higher order oligomeric complex. As we only expressed the ECD domain of RET, we cannot perform the in vitro phosphorylation assays to measure the activity of the purified complex. Nevertheless, we validated our structural models by using the mutagenesis based cellular assays, as shown in Figure 3. All these results consistently support our model.

> 5\) Some additional experimental details are required, in Materials and methods section, to truly make the work reproducible by other workers. This is an important issue because refolding the mature parts of GDNF-family proteins into the active form can be difficult, so it is important that the authors describe in detail how all proteins used in the study were cloned, expressed, refolded, and purified. In particular, for the cloning, expression and purification work, the authors should specify what are the modifications from the published protocol that they allude to in subsection "Protein expression and purification". They should also specify the volumes as well as the compositions of the buffers used for each step, etc. If any proteins required modifications to the protocol used for the other family members, these modifications should be specified. The sequences of all constructs should also be provided. The guide should be: what would another investigator need to know to follow precisely what the authors did and get it to work? Some of this detail can be relegated to Supplementary Information if required.

Point accepted. We have elaborated the method section about the protein refolding. The sequence of all the constructs can be found in the supplementary file as well as in the EMDB/PDB database. All the plasmids used in this work will be provided on request.

> 6\) The AUC data suggest protein aggregation. Did the authors undertake equilibrium studies to ask whether this is a normal reversible interaction? Its relevance is difficult to assess.

Our AUC results in Figure 6E in general do not betray evidence of wholesale, non-specific, non-reversible aggregation. The evidence for this is the lack of aggregated species in the range 15-30 S and the fact that the three different concentrations have the expected amounts of material, i.e. there was no loss due to aggregation/precipitation. Rather, the data are consistent with the reversible, concentration-dependent formation of a discrete entity sedimenting at about 13.5 S. Hydrodynamic scaling laws suggest that this could be a tetramer or pentamer, with the material between 7-10 S representing intermediate forms of the ultimate oligomer that have fast off rates compared to the time-scale of the sedimentation experiment (i.e. k~off~ \> 0.01 s^-1^).

We have revised our text (subsection "Oligomerization of RET in the apo-state") to make this point more clearly.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The reviewers feel the manuscript has been improved, but there are some remaining issues that need to be addressed before acceptance, as outlined below.
>
> 1\) Two of the reviewers remain unconvinced by the data on the effects of NRTN mutations on Erk activation in Figure 5A -- which is an important point concerning the functional relevance of higher-order Ret complexes. We recommend that these data be removed (and the conclusions adjusted accordingly), or else presented with proper description of statistical significance in a way that is standard for this type of experiment. Without demonstration of statistical significance, the data should not be included. If the figure is retained, a dose/response analysis should be included, since the mutations could simply be affecting binding affinity.

Point accepted. We have completely removed the Figure 5A and the related text in the revised manuscript.

> 2\) The authors should include the procedure for the gel filtration experiments shown in new Figure 1---figure supplement 1, in Materials and methods section.

Point accepted. We have rewritten the procedure of the gel filtration experiments in detail in the revised Materials and methods section.

> 3\) Please label identify bands in Figure 1---figure supplement 1. If possible, it would be desirable to show additional characterization data such as SDS-PAGE and analytical SEC chromatograms of each protein by itself, or MS data to show the intact mass of each protein.

Point accepted. We have labelled each protein band in Figure 1---figure supplement 1, and run the SDS-PAGE for each component by itself. This result is shown in Figure 1---figure supplement 1A.

[^1]: These authors contributed equally to this work.
